Olema Pharmaceuticals Becomes Olema Oncology — Shareholders Keep The OLMA Ticker And Valid Certificates
The cancer-drug developer also moved its executive offices to South San Francisco as it prepares for possible palazestrant commercialization.
Olema Pharmaceuticals, which develops targeted therapies for breast cancer and other cancers, became Olema Oncology on Thursday, according to its SEC filing. Shareholders keep the OLMA ticker, and certificates bearing the former name remain valid.
OLMA Stays, Offices Move
Olema's shares continue trading on the Nasdaq Global Select Market. Investors needed to take no action for the rename, and their existing certificates retain their validity.
The board approved a change to the company's Delaware charter and corresponding revisions to its bylaws. Delaware law allowed the name change without a shareholder vote.
Olema also moved its offices Thursday to 365 Oyster Point Boulevard, Suite 400, in South San Francisco. Its principal executive offices were previously at 780 Brannan Street in San Francisco.
Palazestrant Approaches A Trial Readout
Olema is developing palazestrant, an experimental oral breast-cancer treatment, while preparing for its possible commercial launch. President and Chief Executive Officer Sean P. Bohen described the company Tuesday as "preparing for the potential approval and commercialization of palazestrant."
The drug is being tested in patients whose ER-positive, HER2-negative breast cancer has returned, advanced locally or spread. Two pivotal late-stage trials are under way: OPERA-01 tests palazestrant alone, and OPERA-02 tests it with Novartis's ribociclib.
Olema's other candidate, OP-3136, is in an early-stage trial and targets the KAT6 enzyme. The company controls worldwide rights to develop and commercialize both candidates and uses outside manufacturers to make them.
Neither candidate is approved for sale, and Olema has generated no revenue from product sales. Its third-quarter net loss widened to $73.6 million from $42.2 million a year earlier. Cash, cash equivalents and marketable securities totaled $413.8 million at September 30.
Olema expects initial results from its late-stage palazestrant breast-cancer trial in the first quarter of 2027.
Sources
- 8-K Filing — Olema Oncology, Inc. (OLMA) — SEC EDGAR
- Exhibit olma-ex99_1.htm — Olema Oncology, Inc. 8-K exhibit — SEC EDGAR
- Olema Oncology Announces Corporate Name Change — globenewswire.com
- Olema Oncology Reports Third Quarter 2026 Financial and — globenewswire.com